JNJ-2113 is under clinical development by Johnson & Johnson and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback